Sign in
Taking peopleNo phase

EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn

Key facts

Who runs it
Intressa Vascular SA
Where
Austria, Belgium, Bulgaria, France, Germany, Poland, Serbia, and Uzbekistan21 sites in 8 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
72 people, planned
Started
30 Oct 2024
Expected to end
Jun 2031
Type of study
Interventional
Treatments tested
  • Allay Aortic Stent
Record updated
16 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Have a type B aortic dissection extending to the celiac trunk or beyond
  • Are eligible for thoracic endovascular treatment with stent grafts as per local guidelines, and physician's decision
  • Have been elected for treatment with commercially available stent graft as per their IFU within 90 days of dissection symptoms onset

Who cannot take part

  • General Exclusion Criteria:; Age < 18 years; Pregnant, breast-feeding or planning on becoming pregnant during the entire duration of the study; Unable to provide written informed consent; Unable or unwilling to comply with the requirements of the study protocol; Taking part already in an investigational device or drug study that could interfere with the outcomes being studied; Active drug addiction or known history of drug abuse within one year of treatment
  • Medical Exclusion Criteria:; Aortic rupture (free or contained including haemothorax, increasing periaortic hematoma, or mediastinal hematoma); Aortic fistula; Suspicion of bowel necrosis or irreversible visceral ischemia; Stage 5 chronic kidney disease; Life expectancy of less than 2 years due to any other medical condition than the dissection to be treated; Active malignancy; Known sensitivities or allergies to the device materials (including cobalt, chromium, nickel); Known sensitivities or allergies to contrast materials that cannot be pre-medicated; Mycotic aortic aneurysm or active systemic infection that may place the patient at increased risk of endovascular infection; American Society of Anaesthesiologists (ASA) class V (moribund patient not expected to live 24 hours with or without operation); Diagnosed or suspected congenital degenerative connective tissue disease (e.g., Marfan's, Loeys-Dietz or Ehlers-Danlos syndrome); Uncorrectable coagulopathy, bleeding diathesis or refusal of blood transfusion; Any major cardiovascular or cerebrovascular ischemic event, including myocardial infarction or stroke, or treatment of such event, within 90 days prior to enrolment; Any aortic-related interventional or surgical procedure within 30 days prior to enrolment; Any planned aortic-related interventional or surgical procedure within 30 days after the study procedure
  • Anatomical Exclusion Criteria:; Aneurysmal dilatation of the false lumen defined as maximum transaortic diameter >55 mm in women or >60 mm in men in the thoraco-abdominal segment or >50 mm in women or >55 mm in men in the abdominal segment, measured inner-wall to inner-wall; Inadequate proximal landing zone for the stent graft, such zone being <20 mm long; Inadequate proximal landing zone geometry for the Allay® Aortic Stent (e.g. aortic kink); Planned implantation of a stent graft with a distal diameter >38 mm or <20 mm; Aorta or iliac anatomy not allowing the advancement of the delivery system; Subject in whom the thoracic stent graft is either 1) not implanted in its intended position and/or 2) leads to any serious device complication, and/or who has 3) persistent static obstruction of the visceral or both renal arteries, prior to Allay® Aortic Stent implantation, will not be implanted with the Allay® Aortic Stent and will be withdrawn from the study

This trial has no sites in United States.

It has sites in 8 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical trial is a prospective, multicenter, open label study designed to evaluate the effectiveness and the safety of the Allay® Aortic Stent as adjunctive endovascular treatment of Type B aortic dissection in patients eligible for thoracic endovascular aortic repair with stent grafts.

The group in the trial

  • Allay Aortic StentTreatment being tested

    A covered thoracic stent graft is first deployed in supraceliac position as per standard of care then followed by the implantation of the Allay® Aortic Stent deployed from within the stent graft, extending below the celiac trunk to the end of the dissected aorta, typically the aortoiliac bifurcation.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Clinical Study to Evaluate the Effectiveness and Safety of the Allay® Aortic Stent as Adjunctive Endovascular Treatment of Type B Aortic Dissection in Patients Eligible for Thoracic Endovascular Repair With Stent Grafts
Record updated
16 September 2026